Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document


Por: Abdin, A, Bauersachs, J, Abdelhamid, M, Aktaa, S, Al Ghorani, H, Bayes-Genis, A, Biegus, J, Böhm, M, Butler, J, Girerd, N, Metra, M, Mullens, W, Skouri, H, Vaduganathan, M, El Hadidi, S, Rosano, GMC and Savarese, G

Publicada: 1 dic 2025 Ahead of Print: 1 dic 2025
Resumen:
Heart failure (HF) exerts a global health burden, often complicated by polypharmacy due to the frequent coexistence of cardiovascular and non-cardiovascular comorbidities. While guideline-directed medical therapy and devices have significantly improved outcomes, a range of commonly prescribed medications may inadvertently worsen HF or precipitate decompensation. This expert consensus statement provides a comprehensive overview of drugs known to cause or exacerbate HF, offering practical guidance for clinicians to identify and avoid harmful pharmacologic exposures in this vulnerable population. The review examines the pathophysiological mechanisms, clinical evidence, and guideline-based recommendations for several drug classes, including antidiabetic agents (e.g. thiazolidinediones, dipeptidyl peptidase-4 inhibitors), antiarrhythmics (particularly Class I and III), calcium channel blockers, non-steroidal anti-inflammatory drugs, antifungals (e.g. itraconazole, amphotericin B), macrolide antibiotics, antihypertensives (e.g. alpha 1-blockers, centrally acting sympatholytics), neurological and psychiatric medications (e.g. carbamazepine, pregabalin, lithium), and selected anaesthetic and anticancer agents such as anthracyclines and vascular endothelial growth factor inhibitors. Each section addresses clinical scenarios where these medications may be contraindicated or require close monitoring. Importantly, this document emphasizes the need for individualized therapy, close review of medication regimens, and collaborative care to minimize iatrogenic harm. The goal is to empower clinicians, pharmacists and nurses to optimize HF treatment while reducing the risk of drug-induced deterioration. Awareness of these pharmacologic pitfalls is critical to improving clinical outcomes and minimizing preventable adverse events and HF hospitalizations. [GRAPHICS]

Filiaciones:
Abdin, A:
 Saarland Univ Hosp, Internal Med Clin 3, Cardiol Angiol & Intens Care Med, Homburg Saar, Germany

Bauersachs, J:
 Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany

Abdelhamid, M:
 Cairo Univ, Fac Med Kasr Al Ainy, Cardiol Dept, Giza, Egypt

Aktaa, S:
 St Pauls Hosp, Dept Cardiol, Vancouver, BC, Canada

Al Ghorani, H:
 Saarland Univ Hosp, Internal Med Clin 3, Cardiol Angiol & Intens Care Med, Homburg Saar, Germany

:
 Univ Hosp Germans Trias & Pujol, Badalona, Spain

Biegus, J:
 Wroclaw Med Univ, Clin Dept Intens Cardiac Care, Inst Heart Dis, Dept Cardiol,Fac Med, Wroclaw, Poland

Böhm, M:
 Saarland Univ Hosp, Internal Med Clin 3, Cardiol Angiol & Intens Care Med, Homburg Saar, Germany

Butler, J:
 Baylor Scott & White Res Inst, Dallas, TX USA

 Univ Mississippi, Dept Med, Jackson, MS USA

Girerd, N:
 Univ Lorraine, INSERM, CHU Nancy, Vandoeuvre Les Nancy, France

 CardioRenal Integrat Clin Invest Ctr, Vandoeuvre Les Nancy, France

Metra, M:
 Univ Brescia, Cardiol, ASST Spedali Civili, Brescia, Italy

 Univ Brescia, Inst Cardiol, Dept Expt & Appl Med, Brescia, Italy

Mullens, W:
 Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium

 UHasselt Hasselt Univ, Biomed Res Inst, Fac Med & Life Sci, LCRC, Diepenbeek, Belgium

Skouri, H:
 Sheikh Shakhbout Med City, Div Cardiol, Abu Dhabi, U Arab Emirates

 Balamand Univ, Fac Med & Med Sci, Med Dept, Cardiol Div, Balamand, Lebanon

Vaduganathan, M:
 Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA USA

El Hadidi, S:
 Royal Coll Surgeons Ireland, Dublin, Ireland

 Natl Off Clin Audit, Dublin, Ireland

Rosano, GMC:
 San Raffaele Open Univ Rome, Dept Human Sci & Promot Qual Life, Rome, Italy

 IRCCS San Raffaele, Rome, Italy

Savarese, G:
 Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden
ISSN: 13889842





European Journal of Heart Failure
Editorial
Wiley-Blackwell, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 27 Número: 12
Páginas: 2671-2690
WOS Id: 001637772800001
ID de PubMed: 41382384
imagen Green Submitted, hybrid

MÉTRICAS